UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer...
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the...
Analysts fell to the sidelines weighing in on Reata Pharmaceuticals (RETA – Research Report), Turning Point Therapeutics (TPTX – Research Report...
JMP Securities analyst Silvan Tuerkcan maintained a Hold rating on Turning Point Therapeutics (TPTX - Research Report) today. The company's shares...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 ...
--12-312023-05-31Q20001595893 false0001595893us-gaap:CommercialPaperMember2021-12-310001595893us-gaap:LicenseMember2020-07-012020-09-300001595893...
false000159589300015958932022-08-082022-08-08 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA...
SVB Securities analyst Andrew Berens maintained a Hold rating on Turning Point Therapeutics (TPTX – Research Report) on July 27. The company's...
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement...
false 0001595893 0001595893 2022-06-23 2022-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.